X

Drug Profile

AT 307

Alternative Names: AT-307 - Arecor/Hikma Pharmaceuticals

Latest Information Update: 22 Sep 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Arecor; Hikma Pharmaceuticals
Class Peptides; Proteins
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Research Unspecified

Most Recent Events

22 Sep 2022 Early research in Unspecified in USA (Parenteral) (Arecor pipeline, September 2022)
22 Sep 2022 Arecor plans to launch AT 307 from 2024 onward (Arecor pipeline, September 2022)
20 Oct 2020 Hikma Pharmaceuticals announces intention to submit filings for regulatory approval to US FDA in 2023

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com